Intellectual Property and Cumulative Innovation, (with Margaret Kyle, Qiu Ju) 2019.
Has the Shortened Drug Distribution Chain Cut Drug Prices? Evidence from the Implementation of Two-Invoice System in China, (with Xiaoxi Li and Fanyu Liu), Dec. 2022.
The Health Consequences of Pediatric Labeling Changes — Evidence from Pediatric Hospitalization and Adverse Drug Events, (with Mary Olson), March. 2022.
Pharmaceuticals, Incremental Innovation and Market Exclusivity, International Journal of Industrial Organization, Volume 87, March 2023.
The Impact of Antitrust Regulations on Firm Market Value - Evidence from Chinese and U.S. Internet Platforms, (with Yong Huang, Yanhua Zhang and Shan Zhao), Dec. 2022. forthcoming at Review of Industrial Organization.
New Clinical Information and Physician Prescribing: How Do Pediatric Labeling Changes Affect Prescribing to Children? (with Mary K. Olson), Health Economics, 30(1): 144-164, January 2021.
Economic Analysis Under the Anti-Unfair Competition Law in China: Tencent v. Xinhui, (with Vanessa Yanhua Zhang and John Jiong Gong), CPI Antitrust Chronicle, March 2019.
Multitask Assignments with Adverse Selection, (with Minbo Xu, Sanxi Li), Economics Letters, 181:127-132, August 2019.
Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity (with Mary K. Olson),American Journal of Health Economics4(3): 321-357, Summer 2018.
The Impact of Venture Capital on Innovation, (with Roberta Dessi), in D. Cumming, ed., The Oxford Handbook of Venture Capital, Oxford University Press, Chapter 22, 2012.
Socio-economic Status and Chronic Diseases: The Case of Hypertension in China (with Xiaoyan Lei, Yaohui Zhao), China Economic Review , 23 (2012) 105-121.